Differences between rat primary cortical neurons and astrocytes in purine release evoked by ischemic conditions

F. E. Parkinson, C. J.D. Sinclair, T. Othman, N. J. Haughey, Jonathan Geiger

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

In the brain, the levels of adenosine increase up to 100-fold during cerebral ischernia; however, the roles of specific cell types, enzymatic pathways and membrane transport processes in regulating intra- and extracellular concentrations of adenosine are poorly characterized. Rat primary cortical neurons and astrocytes were incubated with [3H]adenine for 30 min to radiolabel intracellular ATP. Cells were then treated with buffer, glucose deprivation (GD), oxygen-glucose deprivation (OGD), 100 μM sodium cyanide (NaCN) or 500 μM iodoacetate (IAA) for 1 h to stimulate the metabolism of ATP and cellular release of [3H]purines. The nucleoside transport inhibitor dipyridamole (DPR) (10 μM), the adenosine kinase inhibitor iodotubercidin (ITU) (1 μM), the adenosine deaminase inhibitor EHNA (1 μM) and the purine nucleoside phosphorylase inhibitor BCX-34 (10 μM) were tested to investigate the contribution of specific enzymes and transporters in the metabolism and release of purines from each cell type. Our results indicate that (a) under basal conditions astrocytes released significantly more [3H]adenine nucleotides and [3H]adenosine than neurons, (b) OGD, NaCN and IAA conditions produced significant increases in [3H]adenosine release from neurons but not astrocytes, and (c) DPR blocked [3H]inosine release from both astrocytes and neurons but only blocked [3H]adenosine release from neurons. These data suggest that, in these experimental conditions, adenosine was formed by an intracellular pathway in neurons and then released via a nucleoside transporter. In contrast, adenine nucleotide release and extracellular metabolism to adenosine appeared to predominate in astrocytes.

Original languageEnglish (US)
Pages (from-to)836-846
Number of pages11
JournalNeuropharmacology
Volume43
Issue number5
DOIs
StatePublished - Oct 1 2002

Fingerprint

Astrocytes
Adenosine
Neurons
Iodoacetates
Purines
Dipyridamole
Adenine Nucleotides
Glucose
Adenosine Triphosphate
Adenosine Deaminase Inhibitors
Sodium Cyanide
Nucleoside Transport Proteins
Adenosine Kinase
Purine-Nucleoside Phosphorylase
Oxygen
Inosine
Adenine
purine
Nucleosides
Buffers

Keywords

  • Adenine nucleotides
  • Adenosine
  • Adenosine deaminase
  • Adenosine kinase
  • Hypoxanthine
  • Inosine
  • Nucleoside transport
  • Purine nucleoside phosphorylase

ASJC Scopus subject areas

  • Pharmacology
  • Cellular and Molecular Neuroscience

Cite this

Differences between rat primary cortical neurons and astrocytes in purine release evoked by ischemic conditions. / Parkinson, F. E.; Sinclair, C. J.D.; Othman, T.; Haughey, N. J.; Geiger, Jonathan.

In: Neuropharmacology, Vol. 43, No. 5, 01.10.2002, p. 836-846.

Research output: Contribution to journalArticle

Parkinson, F. E. ; Sinclair, C. J.D. ; Othman, T. ; Haughey, N. J. ; Geiger, Jonathan. / Differences between rat primary cortical neurons and astrocytes in purine release evoked by ischemic conditions. In: Neuropharmacology. 2002 ; Vol. 43, No. 5. pp. 836-846.
@article{37cd20a7d851424aa4d2eacb909091c8,
title = "Differences between rat primary cortical neurons and astrocytes in purine release evoked by ischemic conditions",
abstract = "In the brain, the levels of adenosine increase up to 100-fold during cerebral ischernia; however, the roles of specific cell types, enzymatic pathways and membrane transport processes in regulating intra- and extracellular concentrations of adenosine are poorly characterized. Rat primary cortical neurons and astrocytes were incubated with [3H]adenine for 30 min to radiolabel intracellular ATP. Cells were then treated with buffer, glucose deprivation (GD), oxygen-glucose deprivation (OGD), 100 μM sodium cyanide (NaCN) or 500 μM iodoacetate (IAA) for 1 h to stimulate the metabolism of ATP and cellular release of [3H]purines. The nucleoside transport inhibitor dipyridamole (DPR) (10 μM), the adenosine kinase inhibitor iodotubercidin (ITU) (1 μM), the adenosine deaminase inhibitor EHNA (1 μM) and the purine nucleoside phosphorylase inhibitor BCX-34 (10 μM) were tested to investigate the contribution of specific enzymes and transporters in the metabolism and release of purines from each cell type. Our results indicate that (a) under basal conditions astrocytes released significantly more [3H]adenine nucleotides and [3H]adenosine than neurons, (b) OGD, NaCN and IAA conditions produced significant increases in [3H]adenosine release from neurons but not astrocytes, and (c) DPR blocked [3H]inosine release from both astrocytes and neurons but only blocked [3H]adenosine release from neurons. These data suggest that, in these experimental conditions, adenosine was formed by an intracellular pathway in neurons and then released via a nucleoside transporter. In contrast, adenine nucleotide release and extracellular metabolism to adenosine appeared to predominate in astrocytes.",
keywords = "Adenine nucleotides, Adenosine, Adenosine deaminase, Adenosine kinase, Hypoxanthine, Inosine, Nucleoside transport, Purine nucleoside phosphorylase",
author = "Parkinson, {F. E.} and Sinclair, {C. J.D.} and T. Othman and Haughey, {N. J.} and Jonathan Geiger",
year = "2002",
month = "10",
day = "1",
doi = "10.1016/S0028-3908(02)00083-7",
language = "English (US)",
volume = "43",
pages = "836--846",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Differences between rat primary cortical neurons and astrocytes in purine release evoked by ischemic conditions

AU - Parkinson, F. E.

AU - Sinclair, C. J.D.

AU - Othman, T.

AU - Haughey, N. J.

AU - Geiger, Jonathan

PY - 2002/10/1

Y1 - 2002/10/1

N2 - In the brain, the levels of adenosine increase up to 100-fold during cerebral ischernia; however, the roles of specific cell types, enzymatic pathways and membrane transport processes in regulating intra- and extracellular concentrations of adenosine are poorly characterized. Rat primary cortical neurons and astrocytes were incubated with [3H]adenine for 30 min to radiolabel intracellular ATP. Cells were then treated with buffer, glucose deprivation (GD), oxygen-glucose deprivation (OGD), 100 μM sodium cyanide (NaCN) or 500 μM iodoacetate (IAA) for 1 h to stimulate the metabolism of ATP and cellular release of [3H]purines. The nucleoside transport inhibitor dipyridamole (DPR) (10 μM), the adenosine kinase inhibitor iodotubercidin (ITU) (1 μM), the adenosine deaminase inhibitor EHNA (1 μM) and the purine nucleoside phosphorylase inhibitor BCX-34 (10 μM) were tested to investigate the contribution of specific enzymes and transporters in the metabolism and release of purines from each cell type. Our results indicate that (a) under basal conditions astrocytes released significantly more [3H]adenine nucleotides and [3H]adenosine than neurons, (b) OGD, NaCN and IAA conditions produced significant increases in [3H]adenosine release from neurons but not astrocytes, and (c) DPR blocked [3H]inosine release from both astrocytes and neurons but only blocked [3H]adenosine release from neurons. These data suggest that, in these experimental conditions, adenosine was formed by an intracellular pathway in neurons and then released via a nucleoside transporter. In contrast, adenine nucleotide release and extracellular metabolism to adenosine appeared to predominate in astrocytes.

AB - In the brain, the levels of adenosine increase up to 100-fold during cerebral ischernia; however, the roles of specific cell types, enzymatic pathways and membrane transport processes in regulating intra- and extracellular concentrations of adenosine are poorly characterized. Rat primary cortical neurons and astrocytes were incubated with [3H]adenine for 30 min to radiolabel intracellular ATP. Cells were then treated with buffer, glucose deprivation (GD), oxygen-glucose deprivation (OGD), 100 μM sodium cyanide (NaCN) or 500 μM iodoacetate (IAA) for 1 h to stimulate the metabolism of ATP and cellular release of [3H]purines. The nucleoside transport inhibitor dipyridamole (DPR) (10 μM), the adenosine kinase inhibitor iodotubercidin (ITU) (1 μM), the adenosine deaminase inhibitor EHNA (1 μM) and the purine nucleoside phosphorylase inhibitor BCX-34 (10 μM) were tested to investigate the contribution of specific enzymes and transporters in the metabolism and release of purines from each cell type. Our results indicate that (a) under basal conditions astrocytes released significantly more [3H]adenine nucleotides and [3H]adenosine than neurons, (b) OGD, NaCN and IAA conditions produced significant increases in [3H]adenosine release from neurons but not astrocytes, and (c) DPR blocked [3H]inosine release from both astrocytes and neurons but only blocked [3H]adenosine release from neurons. These data suggest that, in these experimental conditions, adenosine was formed by an intracellular pathway in neurons and then released via a nucleoside transporter. In contrast, adenine nucleotide release and extracellular metabolism to adenosine appeared to predominate in astrocytes.

KW - Adenine nucleotides

KW - Adenosine

KW - Adenosine deaminase

KW - Adenosine kinase

KW - Hypoxanthine

KW - Inosine

KW - Nucleoside transport

KW - Purine nucleoside phosphorylase

UR - http://www.scopus.com/inward/record.url?scp=0036801703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036801703&partnerID=8YFLogxK

U2 - 10.1016/S0028-3908(02)00083-7

DO - 10.1016/S0028-3908(02)00083-7

M3 - Article

VL - 43

SP - 836

EP - 846

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 5

ER -